ArticleFrontiers in pharmacology2022

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors.

Suying Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.